Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating, Announces Target Price $135
Express News | Lantheus Holdings-Expects to Release Data in Oct 2024 for Splash Trial Based on 75% of Protocol-Specified Target Overall Survival Events Being Reached
Robust Quarterly Result Lifted Lantheus (LNTH) in Q2
Cancer Research Sees Major Boost as New Breakthroughs Emerge From Key Oncology Players
JonesTrading Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $137
JonesTrading analyst Justin Walsh maintains $Lantheus(LNTH.US)$ with a buy rating, and maintains the target price at $137.According to TipRanks data, the analyst has a success rate of 33.7% and a
Buy Rating Reaffirmed for Lantheus Holdings Amid Promising PNT2002 Trial Results